UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of the year.

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

and lupus therapies litifilimab and dapirolizumab pegol. Last month, the FDA ended a five-year drought in new therapies for ALS when it approved Amylyx' Relyvrio (sodium phenylbutyrate and ...

Steroid Use in SLE Half of lupus patients taking dapirolizumab pegol achieved response at week 48 compared with one third of patients taking placebo. Medscape Medical News, November 25 ...